within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX13_Valbenazine;

model Valbenazine
  extends Pharmacolibrary.Drugs.ATC.N.N07XX13;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N07XX13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor used primarily for the treatment of tardive dyskinesia in adults. It is FDA-approved and serves to reduce the severity of abnormal, involuntary movements associated with tardive dyskinesia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults following single and multiple oral doses; subjects were generally healthy or adult patients with tardive dyskinesia.</p><h4>References</h4><ol><li><p>Wang, W, et al., &amp; Tian, J (2022). 9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors. <i>Future medicinal chemistry</i> 14(13) 991–1003. DOI:<a href=\"https://doi.org/10.4155/fmc-2021-0331\">10.4155/fmc-2021-0331</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35638444/\">https://pubmed.ncbi.nlm.nih.gov/35638444</a></p></li><li><p>Wang, W, et al., &amp; Tian, J (2021). (+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia. <i>Frontiers in pharmacology</i> 12 770377–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2021.770377\">10.3389/fphar.2021.770377</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34950030/\">https://pubmed.ncbi.nlm.nih.gov/34950030</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Valbenazine;
